Eckert & Ziegler Extends Ga-68 Activities in Japan
Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K. (Japan).
Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K. (Japan).
Rocketvax AG, together with the German Research Foundation (DFG), has financially supported a study carried out as part of a joint project of the Swiss National Science Foundation (SNSF, National Research Program “Covid-19,” NRP 78) and the German…
When certain connections in the brain do not function correctly, disorders such as Parkinson’s disease, dystonia, obsessive-compulsive disorder (OCD), and Tourette’s syndrome may result. Targeted stimulation of specific areas in the brain can help…
Using data for precision medicine
Scientists still are not sure how neurological symptoms arise in COVID-19. Is it because SARS-CoV-2 infects the brain? Or are these symptoms the result of inflammation in the rest of the body? A study by Charité – Universitätsmedizin Berlin has now…
Deadline: April 26, 2024
MTIP invested $15 million to accelerate Caresyntax's commercial growth and to expand its data-driven surgery platform.
● The Fund’s focus is on healthcare innovations that improve patient outcomes
● Leveraging Earlybird Eagle Eye, a cutting-edge proprietary AI tool, the Fund
gains deal flow and market intelligence
● Uniquely, the only European fund with public…
FyoniBio, Alder Therapeutics, and BioLamina enter Consortium Grant Agreement to Propel Recombinant Human Laminin Development for Clinical Applications
Special receptor cells under the skin enable us to feel pain and touch. But Schwann cells also play a key role in detecting such stimuli, researchers at the Max Delbrück Center report in “Nature Communications.” This discovery opens new avenues for…